Dow Jones

38,736.91

0.07%

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

TCRR

TCR2 Therapeutics (TCRR)

TCR2 Therapeutics Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:TCRR

1 2 3 4 5 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
12/06/2023	06:01	Edgar (US Regulatory)	Termination of Registration of a Class of Security Under Section 12(g) (15-12g)	NASDAQ:TCRR	TCR2 Therapeutics Inc
06/06/2023	05:03	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:TCRR	TCR2 Therapeutics Inc
05/06/2023	15:38	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TCRR	TCR2 Therapeutics Inc
01/06/2023	15:46	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	NASDAQ:TCRR	TCR2 Therapeutics Inc
01/06/2023	15:42	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:TCRR	TCR2 Therapeutics Inc
01/06/2023	15:11	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:TCRR	TCR2 Therapeutics Inc
01/06/2023	08:35	Edgar (US Regulatory)	Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)	NASDAQ:TCRR	TCR2 Therapeutics Inc
30/05/2023	15:22	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:TCRR	TCR2 Therapeutics Inc
24/05/2023	15:57	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:TCRR	TCR2 Therapeutics Inc
11/05/2023	06:17	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:TCRR	TCR2 Therapeutics Inc
11/05/2023	05:30	GlobeNewswire Inc.	TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:TCRR	TCR2 Therapeutics Inc
08/05/2023	15:05	GlobeNewswire Inc.	TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:TCRR	TCR2 Therapeutics Inc
05/05/2023	17:50	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:TCRR	TCR2 Therapeutics Inc
05/05/2023	15:38	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:TCRR	TCR2 Therapeutics Inc
20/04/2023	15:51	Edgar (US Regulatory)	Proxy Statement - Merger or Acquisition (definitive) (defm14a)	NASDAQ:TCRR	TCR2 Therapeutics Inc
23/03/2023	06:52	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:TCRR	TCR2 Therapeutics Inc
23/03/2023	06:17	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:TCRR	TCR2 Therapeutics Inc
23/03/2023	05:30	GlobeNewswire Inc.	TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update	NASDAQ:TCRR	TCR2 Therapeutics Inc
06/03/2023	05:00	GlobeNewswire Inc.	Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors	NASDAQ:TCRR	TCR2 Therapeutics Inc
08/02/2023	05:45	GlobeNewswire Inc.	TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023	NASDAQ:TCRR	TCR2 Therapeutics Inc
05/01/2023	15:15	GlobeNewswire Inc.	TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:TCRR	TCR2 Therapeutics Inc
05/01/2023	07:45	GlobeNewswire Inc.	TCR² Therapeutics Announces Pipeline Priorities for 2023	NASDAQ:TCRR	TCR2 Therapeutics Inc
23/11/2022	05:45	GlobeNewswire Inc.	TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference	NASDAQ:TCRR	TCR2 Therapeutics Inc
18/11/2022	15:08	Edgar (US Regulatory)	Amended Tender Offer Statement by Issuer (sc To-i/a)	NASDAQ:TCRR	TCR2 Therapeutics Inc
09/11/2022	02:25	TipRanks	Mizuho Securities Sticks to Their Buy Rating for TCR2 Therapeutics (TCRR)	NASDAQ:TCRR	TCR2 Therapeutics Inc
08/11/2022	10:36	TipRanks	SVB Securities Keeps Their Hold Rating on TCR2 Therapeutics (TCRR)	NASDAQ:TCRR	TCR2 Therapeutics Inc
08/11/2022	05:45	GlobeNewswire Inc.	TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update	NASDAQ:TCRR	TCR2 Therapeutics Inc
07/11/2022	07:01	GlobeNewswire Inc.	TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer	NASDAQ:TCRR	TCR2 Therapeutics Inc
19/10/2022	15:16	Edgar (US Regulatory)	Tender Offer Statement by Issuer (sc To-i)	NASDAQ:TCRR	TCR2 Therapeutics Inc
29/09/2022	05:25	TipRanks	TCR2 Therapeutics (TCRR) Gets a Buy from H.C. Wainwright	NASDAQ:TCRR	TCR2 Therapeutics Inc